Top

Published in:

01-05-2010 | Original Article

Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis

Authors: Shihoko Okazaki, Fumihide Ogawa, Yohei Iwata, Toshihide Hara, Eiji Muroi, Kazuhiro Komura, Motoi Takenaka, Kazuhiro Shimizu, Minoru Hasegawa, Manabu Fujimoto, Shinichi Sato

Published in: Rheumatology International | Issue 7/2010

Abstract

The objective of the study was to determine the presence or levels of antibodies (Abs) against caspase-3 and their clinical relevance in systemic sclerosis (SSc). Anti-caspase-3 Ab was examined by enzyme-linked immunosorbent assay and immunoblotting. IgG anti-caspase-3 Ab levels in SSc patients were higher than in normal controls. SSc patients positive for IgG anti-caspase-3 Ab had significantly longer disease duration, more frequent presence of decreased %VC and %DLco, and elevated levels of serum immunoglobulin and erythrocyte sedimentation rates. IgG anti-caspase-3 Ab levels correlated positively with serum IgG levels, renal vascular resistance, and serum levels of 8-isoprostane. Immunoblotting analysis confirmed the presence of anti-caspase-3 Ab in sera from SSc patients. Caspase-3 enzymatic activity was inhibited by IgG isolated from SSc sera containing IgG anti-caspase-3 Ab. These results suggest that autoantibody against caspase-3 is generated in SSc and that this Ab is related to the severity of pulmonary fibrosis, vascular damage, and inflammation.

Okano Y (1996) Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 22:709–735CrossRefPubMed

Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:80–93PubMed

Koenig M, Dieude M, Senecal JL (2008) Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 7:588–593CrossRefPubMed

Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H (2008) Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr 158:19–28CrossRefPubMed

Iwata Y, Ogawa F, Komura K, Muroi E, Hara T, Shimizu K et al (2007) Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology 46:790–795CrossRefPubMed

Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K et al (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138:357–363CrossRefPubMed

Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120:542–547CrossRefPubMed

Matucci Cerinic M, Kahaleh MB (2002) Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology 41:843–847CrossRefPubMed

Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550–2562CrossRefPubMed

10.

Boatright KM, Salvesen GS (2003) Mechanisms of caspase activation. Curr Opin Cell Biol 15:725–731CrossRefPubMed

11.

Nadiri A, Wolinski MK, Saleh M (2006) The inflammatory caspases: key players in the host response to pathogenic invasion and sepsis. J Immunol 177:4239–4245PubMed

12.

Fang B, Boross PI, Tozser J, Weber IT (2006) Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition. J Mol Biol 360:654–666CrossRefPubMed

13.

Ni CZ, Li C, Wu JC, Spada AP, Ely KR (2003) Conformational restrictions in the active site of unliganded human caspase-3. J Mol Recognit 16:121–124CrossRefPubMed

14.

Sisto M, Lisi S, Castellana D, Scagliusi P, D’Amore M, Caprio S et al (2006) Autoantibodies from Sjogren’s syndrome induce activation of both the intrinsic and extrinsic apoptotic pathways in human salivary gland cell line A-253. J Autoimmun 27:38–49CrossRefPubMed

15.

Yamamoto T, Nishioka K (2004) Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 122:44–50CrossRefPubMed

16.

Elizabeth AS, Colon A, Seamus JM (2001) Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276:7320–7326CrossRef

17.

Sabbagh L, Kaech SM, Bourbonniere M, Woo M, Cohen LY, Haddad EK et al (2004) The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol 173:5425–5433PubMed

18.

Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F (2006) Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus. Cell Immunol 239:121–128CrossRefPubMed

19.

Cipriani P, Fulminis A, Pingiotti E, Marrelli A, Liakouli V, Perricone R et al (2006) Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis. J Rheumatol 33:2003–2014PubMed

20.

Ueki A, Isozaki Y, Tomokuni A, Hatayama T, Ueki H, Kusaka M et al (2002) Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol 129:556–561CrossRefPubMed

21.

(1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581–590

22.

LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205PubMed

23.

Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892–1896PubMed

24.

Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 37:391–394CrossRefPubMed

25.

Nishijima C, Sato S, Hasegawa M, Nagaoka T, Hirata A, Komatsu K et al (2001) Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology 40:109–406CrossRef

26.

Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635–6643PubMed

27.

Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K et al (2006) Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 45:815–818CrossRefPubMed

28.

Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K et al (1993) Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 36:1137–1141CrossRefPubMed

29.

Morrow JD, Roberts LJ 2nd (1996) The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 51:1–9CrossRefPubMed

30.

Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792CrossRefPubMed

31.

Casiano CA, Martin SJ, Green DR, Tan EM (1996) Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 184:765–770CrossRefPubMed

32.

Panchenko MV, Farber HW, Korn JH (2000) Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol 278:C92–C101PubMed

33.

Suematsu M, Wakabayashi Y, Ishimura Y (1996) Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovasc Res 32:679–686PubMed

34.

Butler AR, Flitney FW, Williams DL (1995) NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist’s perspective. Trends Pharmacol Sci 16:18–22CrossRefPubMed

35.

Dosreis GA, Borges VM, Zin WA (2004) The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med 8:285–293CrossRefPubMed

36.

Hagimoto N, Kuwano K, Inoshima I, Yoshimi M, Nakamura N, Fujita M et al (2002) TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 168:6470–6478PubMed

37.

Plataki M, Koutsopoulos AV, Darivianaki K, Delides G, Siafakas NM, Bouros D (2005) Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 127:266–274CrossRefPubMed

38.

Nagy G, Koncz A, Perl A (2005) T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25:123–140CrossRefPubMed

Title: Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis
Authors: Shihoko Okazaki
Fumihide Ogawa
Yohei Iwata
Toshihide Hara
Eiji Muroi
Kazuhiro Komura
Motoi Takenaka
Kazuhiro Shimizu
Minoru Hasegawa
Manabu Fujimoto
Shinichi Sato
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 7/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-009-1068-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2010

Demographic, clinical and mutational characteristics of Turkish familial Mediterranean fever patients: results of a single center in Central Anatolia

The relationship between disease activity and depression in patients with Behcet disease and rheumatoid arthritis

Diffuse lupus encephalopathy in a case of rhupus syndrome

Macrophagic myofascitis associated with rheumatoid arthritis

Psychometric properties evaluation of the childhood health assessment questionnaire (CHAQ) in Moroccan juvenile idiopathic arthritis

Charcot’s arthropathy secondary to herpetic encephalitis sequelae: an unusual presentation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials